Establishment of a mouse model of acute liver failure induced by LPS/D-GalN
Received:January 21, 2014  
View Full Text  View/Add Comment  Download reader
DOI:10.3969/j.issn.1005-4847.2014.03.003
KeyWord:Lipopolysaccharide, LPS;D-galactosamine, D-GalN;Acute liver failure;Inflammation;Mouse
                    
AuthorInstitution
吴小红 病原微生物生物安全国家重点实验室, 北京微生物流行病研究所, 北京
郭彦 病原微生物生物安全国家重点实验室, 北京微生物流行病研究所, 北京
刘晨风 病原微生物生物安全国家重点实验室, 北京微生物流行病研究所, 北京 ;安徽医科大学北京微生物流行病研究所, 合肥
高同同 病原微生物生物安全国家重点实验室, 北京微生物流行病研究所, 北京
于虹 病原微生物生物安全国家重点实验室, 北京微生物流行病研究所, 北京
孙世惠 病原微生物生物安全国家重点实验室, 北京微生物流行病研究所, 北京
周育森 病原微生物生物安全国家重点实验室, 北京微生物流行病研究所, 北京
Hits: 1828
Download times: 602
Abstract:
      Objective To establish a mouse model of acute liver failure induced by lipopolysaccharide/D-galactosamine (LPS/D-GalN). Methods The optimum dose of LPS/D-GalN was determined by i.p. injection of eight different doses of LPS and D-GalN into 40 female C57BL/6 mice and observation of their survival time. Then, 32 female C57BL/6 mice were i.p. injected with the optimal dose of LPS/D-GalN and sacrificed at 0, 1, 4, 8 hours after the injection, 8 mice in each group. The control mice received saline injection. Hepatic changes were observed by pathology and serum ALT, IL-6, MCP-1 and TNF-α were measured by biochemistry or flow cytometry. Results LPS (2.5 mg/kg) and D-GalN (0.3 g/kg) were determined as the optimal dose for the establishment of mouse model of acute liver injury. Compared with the control group, the hepatocellular damages were progressing in a positive correlation with the time course after LPS/D-GalN administration. The level of serum ALT was significantly increased after LPS/D-GalN administration(P<0.001). The levels of inflammatory cytokines IL-6, MCP-1 and TNF-α were increased and reached a peak at one hour after LPS/D-GalN administration and then decreased almost to that of the control group 8 hours later(P<0.001). Conclusions The mouse model of acute liver injury is successfully established by LPS/D-GalN administration, and provide an effective animal model for the study of pathogenic mechanisms of acute liver failure and evaluation of therapeutic drugs.
Close
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=909BCF45EAE28FE889FFC352FC5C360F015BD85A4F064474BA31062F1909E5CF1F0959479036DD7529E4584905D890A2EA1E53CC0B92D9A2483DE19498D44F878BBDA9A63AE966F5FC4234CD40F3DB5C&pcid=&cid=&jid=&yid=9EAD63ADE6B277ED&aid=&vid=&iid=38B194292C032A66&sid=23CCDDCD68FFCC2F&eid=2A8D03AD8076A2E3&fileno=20140303&flag=1&is_more=0"> var my_pcid=""; var my_cid=""; var my_jid=""; var my_yid="9EAD63ADE6B277ED"; var my_aid="";